CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer

CCL19型 免疫疗法 医学 三阴性乳腺癌 免疫系统 树突状细胞 乳腺癌 肿瘤微环境 CD8型 癌症研究 免疫学 癌症免疫疗法 肿瘤科 癌症 内科学 趋化因子 趋化因子受体
作者
Siyu Wu,Si-Wei Zhang,Ding Ma,Yi Xiao,Liu Yin,Li Chen,Xiao-Qing Song,Xiao-Yan Ma,Ying Xu,Wen-Jun Chai,Xi Jin,Zhi-Ming Shao,Yi‐Zhou Jiang
出处
期刊:Med [Elsevier]
卷期号:4 (6): 373-393.e8 被引量:6
标识
DOI:10.1016/j.medj.2023.04.008
摘要

Background The extensive involvement of dendritic cells (DCs) in immune contexture indicates their potent value in cancer immunotherapy. Understanding DC diversity in patient cohorts may strengthen the clinical benefit of immune checkpoint inhibitors (ICIs). Methods Single-cell profiling of breast tumors from two clinical trials was performed to investigate DC heterogeneity. Multiomics, tissue characterization, and pre-clinical experiments were used to evaluate the role of the identified DCs in the tumor microenvironment. Four independent clinical trials were leveraged to explore biomarkers to predict ICI and chemotherapy outcomes. Findings We identified a distinct CCL19-expressing functional state of DCs associated with favorable responses to anti-programmed death (ligand)-1 (PD-(L)1), which displayed migratory and immunomodulatory phenotypes. These cells were correlated with antitumor T cell immunity and the presence of tertiary lymphoid structures and lymphoid aggregates, defining immunogenic microenvironments in triple-negative breast cancer. In vivo, CCL19+ DC deletion by Ccl19 gene ablation dampened CCR7+CD8+ T cells and tumor elimination in response to anti-PD-1. Notably, high circulating and intratumoral CCL19 levels were associated with superior response and survival in patients receiving anti-PD-1 but not chemotherapy. Conclusions We uncovered a critical role of DC subsets in immunotherapy, which has implications for designing novel therapies and patient stratification strategies. Funding This study was funded by the National Key Research and Development Project of China, the National Natural Science Foundation of China, the Program of Shanghai Academic/Technology Research Leader, the Natural Science Foundation of Shanghai, the Shanghai Key Laboratory of Breast Cancer, the Shanghai Hospital Development Center (SHDC), and the Shanghai Health Commission.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lk发布了新的文献求助10
1秒前
大个应助忠于人民忠于党采纳,获得30
2秒前
wxy发布了新的文献求助10
2秒前
3秒前
大个应助科研通管家采纳,获得10
3秒前
我是老大应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
英姑应助科研通管家采纳,获得10
4秒前
陈军应助科研通管家采纳,获得20
4秒前
星辰大海应助科研通管家采纳,获得10
4秒前
Akim应助科研通管家采纳,获得10
4秒前
4秒前
Akim应助科研通管家采纳,获得10
4秒前
可靠的书桃应助hlll采纳,获得10
4秒前
SciGPT应助科研通管家采纳,获得10
4秒前
斯文败类应助科研通管家采纳,获得10
5秒前
所所应助科研通管家采纳,获得10
5秒前
研友_VZG7GZ应助科研通管家采纳,获得10
5秒前
Hello应助Chrisiu采纳,获得10
5秒前
小二郎应助科研通管家采纳,获得10
5秒前
FashionBoy应助科研通管家采纳,获得30
5秒前
隐形曼青应助科研通管家采纳,获得10
5秒前
852应助科研通管家采纳,获得10
5秒前
科目三应助科研通管家采纳,获得10
5秒前
6秒前
自觉誉发布了新的文献求助10
6秒前
huhu完成签到,获得积分10
7秒前
豆豆应助huizi采纳,获得10
8秒前
遇见胡桃夹子完成签到,获得积分10
8秒前
思源应助舒适皮皮虾采纳,获得10
8秒前
多发paper啊完成签到,获得积分10
8秒前
木缘完成签到 ,获得积分10
8秒前
9秒前
9秒前
无奈善愁发布了新的文献求助10
11秒前
xjcy应助落寞皓轩采纳,获得20
11秒前
easypass完成签到 ,获得积分20
12秒前
林离发布了新的文献求助50
13秒前
15秒前
15秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3135300
求助须知:如何正确求助?哪些是违规求助? 2786282
关于积分的说明 7776733
捐赠科研通 2442250
什么是DOI,文献DOI怎么找? 1298501
科研通“疑难数据库(出版商)”最低求助积分说明 625124
版权声明 600847